Differences in Trans-stimulated Chloroquine Efflux Kinetics Are Linked to PfCRT in Plasmodium Falciparum
Overview
Molecular Biology
Authors
Affiliations
The mechanism underpinning chloroquine drug resistance in the human malarial parasite Plasmodium falciparum has remained controversial. Currently discussed models include a carrier or a channel for chloroquine, the former actively expelling the drug, the latter facilitating its passive diffusion, out of the parasite's food vacuole, where chloroquine accumulates and inhibits haem detoxification. Here we have challenged both models using an established trans-stimulation efflux protocol. While carriers may demonstrate trans-stimulation, channels do not. Our data reveal that extracellular chloroquine stimulates chloroquine efflux in the presence and absence of metabolic energy in both chloroquine-sensitive and -resistant parasites, resulting in a hyperbolic increase in the apparent initial efflux rates as the concentration of external chloroquine increases. In the absence of metabolic energy, the apparent initial efflux rates were comparable in both parasites. Significant differences were only observed in the presence of metabolic energy, where consistently higher apparent initial efflux rates were found in chloroquine-resistant parasites. As trans-stimulation is characteristic of a carrier, and not a channel, we interpret our data in favour of a carrier for chloroquine being present in both chloroquine-sensitive and -resistant parasites, however, with different transport modalities.
Tarama C, Sore H, Siribie M, Debe S, Kinda R, Ganou A Malar J. 2023; 22(1):213.
PMID: 37474966 PMC: 10360335. DOI: 10.1186/s12936-023-04645-9.
Berger F, Gomez G, Sanchez C, Posch B, Planelles G, Sohraby F Nat Commun. 2023; 14(1):4234.
PMID: 37454114 PMC: 10349806. DOI: 10.1038/s41467-023-39969-2.
Willems A, Kalaw A, Ecer A, Kotwal A, Roepe L, Roepe P Biochemistry. 2023; 62(5):1093-1110.
PMID: 36800498 PMC: 10950298. DOI: 10.1021/acs.biochem.2c00669.
Smirnova M, Goracci L, Cruciani G, Federici L, Decleves X, Chapy H Pharmaceutics. 2022; 14(2).
PMID: 35213988 PMC: 8875908. DOI: 10.3390/pharmaceutics14020255.
Antimalarial Drug Resistance and Novel Targets for Antimalarial Drug Discovery.
Adigo Shibeshi M, Kifle Z, Atnafie S Infect Drug Resist. 2020; 13:4047-4060.
PMID: 33204122 PMC: 7666977. DOI: 10.2147/IDR.S279433.